Pharmaceutical composition for treating helicobacter pylori infection and application of pharmaceutical composition

Abstract

The invention discloses a pharmaceutical composition for treating helicobacter pylori infection and application of the pharmaceutical composition. The pharmaceutical composition is prepared from, by weight, 7.5-40 parts of proton pump inhibitor, 150-1000 parts of antibiotic, 220-300 parts of bismuth agent and 60-140 parts of volatile extracts, wherein the proton pump inhibitor is selected from one of omeprazole, lansoprazole, esomeprazole, pantoprazole and rabeprazole; the antibiotic is selected from one of amoxicillin, clarithromycin, levofloxacin, metronidazole, furazolidone, tetracycline and minocycline; the bismuth agent is selected from one of bismuth potassium citrate, colloidal bismuth subcitrate and colloidal bismuth pectin; the volatile extracts are volatile components extracted from chenopodium ambrosioides and twigs and leaves of Pilular Adina. By means of the pharmaceutical composition, the eradication rate of helicobacter pylori can be improved, the effective rate is increased, and the drug resistance rate and the rate of adverse reactions are reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating Helicobacter pylori infection, and also relates to the application of the pharmaceutical composition. Background technique [0002] Helicobacter pylori (H. pylori) is a helical, slightly anaerobic, Gram-negative bacillus that requires very harsh growth conditions. It is the only microbial species known to survive in the human stomach. In 1982, Australian scholars Marshall and Warren discovered H. pylori and clarified the role of H. pylori in gastritis and peptic ulcer disease. In 1994, the World Health Organization officially identified H. pylori as a class I (ie definite) carcinogen. The discovery of H. pylori has revolutionized the world's understanding of gastric diseases, treatment concepts and methods, making gastroduodenal diseases, especially peptic ulcer disease, no longer a long-term, incurable and frequent recurrence disease. disease and become curable with only short-course...

AI Technical Summary

Problems solved by technology

Due to factors such as the abuse of antibiotics, irregular treatment plans, and poor control of eradication indications, the problem of drug resistance of Helicobacter pylori is becoming more and more serious, and the eradication rate is also declining.